In the PACIFIC trial, the addition of adjuvant durvalumab, an anti-PD-L1 mAb, to definitive CRT for Stage III NSCLC resulted in improved survival compared with standard CRT [46]; thus, immunochemoradiotherapy has become a standard of care for NSCLC [47]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.